Cargando…

HER2 Amplification by Next-Generation Sequencing in Lung Carcinoma: A Comparison of NGS Amplified and Non-amplified Cases by Immunohistochemistry and In Situ Hybridization

BACKGROUND: Although the role of HER2 amplification and its evaluation methods are well known in breast carcinoma, methods for detection of HER2 amplification in non-small cell lung carcinoma are unclear. Next-generation sequencing is widely used in searching multiple therapeutic targets, and it is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kıvrak, Hale, Özakıncı, Hilal, Karasoy, Duru, Dizbay Sak, Serpil
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Galenos Publishing 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8941247/ https://www.ncbi.nlm.nih.gov/pubmed/34928234 http://dx.doi.org/10.5152/balkanmedj.2021.21144

Ejemplares similares

HER-2/neu Amplification Testing in Breast Cancer by Multiplex Ligation-Dependent Probe Amplification in Comparison with Immunohistochemistry and In Situ Hybridization
por: Moelans, Cathy B., et al.
Publicado: (2009)

Determination of the HER2 amplification status by in situ fluorescent hybridization and concordance with immunohistochemistry for breast cancer samples in Colombia
por: Plata, Adriana, et al.
Publicado: (2013)

In situ amplification of spin echoes within a kinetic inductance parametric amplifier
por: Vine, Wyatt, et al.
Publicado: (2023)

Low Level of Her-2 Locus Amplification by Fluorescent In Situ Hybridization Does Not Correlate with Her-2 Protein Overexpression by Immunohistochemistry in Barrett's Esophagus
por: Rygiel, Agnieszka M., et al.
Publicado: (2010)

A CT-Based Radiomic Signature for the Differentiation of Pulmonary Hamartomas from Carcinoid Tumors
por: Cangir, Ayten Kayi, et al.
Publicado: (2022)

Amplified RNA degradation in T7-amplification methods results in biased microarray hybridizations
por: Spiess, Andrej-Nikolai, et al.
Publicado: (2003)

Is HER2 amplification predictable by digital immunohistochemistry?
por: Micsik, Tamás, et al.
Publicado: (2013)

Evaluating HER2 Gene Amplification Using Chromogenic In Situ Hybridization (CISH) Method In Comparison To Immunohistochemistry Method in Breast Carcinoma
por: Atabati, Hadi, et al.
Publicado: (2018)

Fatal Invasive Aspergillosis in a Child with Idiopathic Pulmonary Hemosiderosis
por: Kahveci, Fevzi, et al.
Publicado: (2023)

HER-3 expression in HER-2-amplified breast carcinoma
por: Czopek, Jacek, et al.
Publicado: (2013)

HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
por: Morsberger, Laura, et al.
Publicado: (2022)

Individualized therapy based on the combination of mini-PDX and NGS for a patient with metastatic AFP-producing and HER-2 amplified gastric cancer
por: Zhu, Xiaodan, et al.
Publicado: (2022)

Evaluation of gene amplification and protein expression of HER-2/neu in esophageal squamous cell carcinoma using Fluorescence in situ Hybridization (FISH) and immunohistochemistry
por: Sato-Kuwabara, Yukie, et al.
Publicado: (2009)

Hybrid amplifier for calorimetry with photodiode readout
por: Sushkov, V V
Publicado: (1994)

Eukaryotic Cell Capture by Amplified Magnetic in situ Hybridization Using Yeast as a Model
por: Bastian, Fabiola, et al.
Publicado: (2021)

The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers
por: Majumder, Avisek, et al.
Publicado: (2021)

The use of multiple displacement amplification to amplify complex DNA libraries
por: Fullwood, Melissa J., et al.
Publicado: (2008)

HER2 Status by Standardized Immunohistochemistry and Silver-Enhanced In Situ Hybridization in Korean Breast Cancer
por: Bae, Young Kyung, et al.
Publicado: (2012)

Clinical and molecular characterization of HER2 amplified-pancreatic cancer
por: Chou, Angela, et al.
Publicado: (2013)

Inactivating Amplified HER2: Challenges, Dilemmas, and Future Directions
por: Moasser, Mark M.
Publicado: (2022)

Concomitant Detection of HER2 Protein and Gene Alterations by Immunohistochemistry (IHC) and Silver Enhanced In Situ Hybridization (SISH) Identifies HER2 Positive Breast Cancer with and without Gene Amplification
por: Varga, Zsuzsanna, et al.
Publicado: (2014)

MYCN is amplified during S phase, and c-myb is involved in controlling MYCN expression and amplification in MYCN-amplified neuroblastoma cell lines
por: Aygun, Nevim, et al.
Publicado: (2019)

Targetable HER3 functions driving tumorigenic signaling in HER2-amplified cancers
por: Campbell, Marcia R., et al.
Publicado: (2022)

A low-threshold hybrid amplifier-discriminator
por: Santiard, Jean-Claude
Publicado: (1982)

HER2 overexpression/amplification status in colorectal cancer: a comparison between immunohistochemistry and fluorescence in situ hybridization using five different immunohistochemical scoring criteria
por: Sun, Qi, et al.
Publicado: (2022)

Accurate variant detection across non-amplified and whole genome amplified DNA using targeted next generation sequencing
por: ElSharawy, Abdou, et al.
Publicado: (2012)

Breast carcinomas with low amplified/equivocal HER2 by Ish: potential supporting role of multiplex ligation-dependent probe amplification
por: Ercolani, Cristiana, et al.
Publicado: (2017)

Confirmation of a low HER2 positivity rate of breast carcinomas - limitations of immunohistochemistry and in situ hybridization
por: Vogel, Ulrich F
Publicado: (2010)

Comparison of immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) assessment for Her-2 status in breast cancer
por: Sui, Weiguo, et al.
Publicado: (2009)

Fluorescent amplification for next generation sequencing (FA-NGS) library preparation
por: Chiniquy, Jennifer, et al.
Publicado: (2020)

An ultra-high gain and efficient amplifier based on Raman amplification in plasma
por: Vieux, G., et al.
Publicado: (2017)

Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer
por: Canonici, Alexandra, et al.
Publicado: (2013)

Morphological and molecular characteristics of HER2 amplified urothelial bladder cancer
por: Tschui, J., et al.
Publicado: (2015)

Transcriptome and genome evolution during HER2-amplified breast neoplasia
por: Lu, Peipei, et al.
Publicado: (2021)

Silver-Enhanced In Situ Hybridization as an Alternative to Fluorescence In Situ Hybridization for Assaying HER2 Amplification in Clinical Breast Cancer
por: Park, Kyeongmee, et al.
Publicado: (2011)

Next-generation sequencing, should I use anti-HER2 therapy for HER2-amplified tumors off-label? Illustrating an extrapolation framework
por: Cho, Doah, et al.
Publicado: (2022)

Cervical Paraganglioma Mimicking Thyroid Nodule: A Rare Clinical Case
por: Aydoğan, Berna İmge, et al.
Publicado: (2016)

ALK Gene Rearrangements in Lung Adenocarcinomas: Concordance of Immunohistochemistry, Fluorescence In Situ Hybridization, RNA In Situ Hybridization, and RNA Next-Generation Sequencing Testing
por: Canterbury, Carleigh R., et al.
Publicado: (2021)

S-band hybrid amplifiers based on hydrogenated diamond FETs
por: Ciccognani, Walter, et al.
Publicado: (2020)

CT imaging-based machine learning model: a potential modality for predicting low-risk and high-risk groups of thymoma: “Impact of surgical modality choice”
por: Kayi Cangir, Ayten, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_35n5dpl72vc0rr6737e4q5ts2u